Anabel Goulding1, Lina Asmar2, Yunfei Wang2, Shannon Tole1, Lora Barke3, Jodi Widner4, Charles Leonard1. 1. Radiation Oncology, Rocky Mountain Cancer Centers, Denver, CO, United States. 2. Statistics, Linasmar Consulting, Houston, TX, United States. 3. Radiology, Invision Sally Jobe, Greenwood Village, CO, United States. 4. Surgery, SurgOne, Greenwood Village, CO, United States.
Abstract
PURPOSE: To report a primary objective clinical outcome of ipsilateral breast recurrence following accelerated partial breast irradiation (APBI) in women with triple negative and other high risk breast cancer (as described in 2017 ASTRO guidelines) (i.e., age 40-49, size 2.1-3.0 cm, estrogen receptor negative and invasive lobular breast cancer). Secondary objectives of axillary and regional failure as well as overall survival are also reported. METHODS AND MATERIAL: Patients from two clinical trials (NCT01185145, NCT01185132) were treated with 38.5 Gy IMRT or 3D-CRT APBI w/3.85 Gy fraction/BID fractionation for 10 fractions. Triple negative and other high risk patients (n=269) were compared to a total of 478 low risk patients which ASTRO defined as "suitable" for APBI. High risk patients, for the purpose of this study, were defined as those who possess one or more high risk criteria: triple negative (n=30), tumor size >2 cm <3 cm (n=50), HER 2+ (n=54), age range 40-50 years (n=120), ER- (n=43), and ILC histology (n=52). RESULTS: Median follow up was 4.0 years for all patients. No significant difference was found for this high-risk cohort at 5 years for ipsilateral breast, or regional recurrences. Axillary recurrence was significantly adversely impacted by triple negative and ER- statuses (p=0.01, p=0.04). There were significant correlations between triple negative type and axillary recurrence on multivariate analysis (p=0.03). Overall survival for all patients was unaffected by any of the high-risk categories. CONCLUSION: The data from this study suggests that women possessing high risk features are at no more meaningful risk for recurrence than other patients considered to be acceptable for APBI treatment. However, the finding of axillary recurrence in patients with triple negative breast cancer does warrant a degree of caution in proceeding with accelerated partial breast irradiation technique in this patient group.
PURPOSE: To report a primary objective clinical outcome of ipsilateral breast recurrence following accelerated partial breast irradiation (APBI) in women with triple negative and other high risk breast cancer (as described in 2017 ASTRO guidelines) (i.e., age 40-49, size 2.1-3.0 cm, estrogen receptor negative and invasive lobular breast cancer). Secondary objectives of axillary and regional failure as well as overall survival are also reported. METHODS AND MATERIAL: Patients from two clinical trials (NCT01185145, NCT01185132) were treated with 38.5 Gy IMRT or 3D-CRT APBI w/3.85 Gy fraction/BID fractionation for 10 fractions. Triple negative and other high risk patients (n=269) were compared to a total of 478 low risk patients which ASTRO defined as "suitable" for APBI. High risk patients, for the purpose of this study, were defined as those who possess one or more high risk criteria: triple negative (n=30), tumor size >2 cm <3 cm (n=50), HER 2+ (n=54), age range 40-50 years (n=120), ER- (n=43), and ILC histology (n=52). RESULTS: Median follow up was 4.0 years for all patients. No significant difference was found for this high-risk cohort at 5 years for ipsilateral breast, or regional recurrences. Axillary recurrence was significantly adversely impacted by triple negative and ER- statuses (p=0.01, p=0.04). There were significant correlations between triple negative type and axillary recurrence on multivariate analysis (p=0.03). Overall survival for all patients was unaffected by any of the high-risk categories. CONCLUSION: The data from this study suggests that women possessing high risk features are at no more meaningful risk for recurrence than other patients considered to be acceptable for APBI treatment. However, the finding of axillary recurrence in patients with triple negative breast cancer does warrant a degree of caution in proceeding with accelerated partial breast irradiation technique in this patient group.
Keywords:
HER2 breast cancer +; estrogen receptor negative breast cancer; infiltrating lobular breast cancer; partial breast external beam radiotherapy; triple negative breast cancer; young age group
Authors: Farrell C Adkins; Ana Maria Gonzalez-Angulo; Xiudong Lei; Leonel F Hernandez-Aya; Elizabeth A Mittendorf; Jennifer K Litton; Jamie Wagner; Kelly K Hunt; Wendy A Woodward; Funda Meric-Bernstam Journal: Ann Surg Oncol Date: 2011-09-27 Impact factor: 5.344
Authors: Tari S Stull; M Catherine Goodwin; Edward J Gracely; Michael R Chernick; Richard J Carella; Thomas G Frazier; Andrea V Barrio Journal: Ann Surg Oncol Date: 2011-07-19 Impact factor: 5.344
Authors: L Livi; I Meattini; C Saieva; S Borghesi; V Scotti; A Petrucci; A Rampini; L Marrazzo; V Di Cataldo; S Bianchi; L Cataliotti; G Biti Journal: Eur J Surg Oncol Date: 2010-06-05 Impact factor: 4.424
Authors: Candace Correa; Eleanor E Harris; Maria Cristina Leonardi; Benjamin D Smith; Alphonse G Taghian; Alastair M Thompson; Julia White; Jay R Harris Journal: Pract Radiat Oncol Date: 2016-09-17
Authors: Rachel Y Lei; Charles E Leonard; Kathryn T Howell; Phyllis L Henkenberns; Timothy K Johnson; Tracy L Hobart; Shannon P Fryman; Jane M Kercher; Jodi L Widner; Terese Kaske; Dennis L Carter Journal: Breast Cancer Res Treat Date: 2013-07-04 Impact factor: 4.872
Authors: Charlotte E Coles; Clare L Griffin; Anna M Kirby; Jenny Titley; Rajiv K Agrawal; Abdulla Alhasso; Indrani S Bhattacharya; Adrian M Brunt; Laura Ciurlionis; Charlie Chan; Ellen M Donovan; Marie A Emson; Adrian N Harnett; Joanne S Haviland; Penelope Hopwood; Monica L Jefford; Ronald Kaggwa; Elinor J Sawyer; Isabel Syndikus; Yat M Tsang; Duncan A Wheatley; Maggie Wilcox; John R Yarnold; Judith M Bliss Journal: Lancet Date: 2017-08-02 Impact factor: 79.321